ACAD (ACADIA Pharmaceuticals Inc) Bathi resik saben saham (EPS TTM)

The TTM net income per share metric demonstrates the dynamics of per-share earnings, where the value of 2.09 characterizes this level. The biopharmaceutical business of ACAD Pharmaceuticals (ACAD) focuses on the therapy of CNS disorders, leveraging exclusive rights to unique drugs. The company monetizes treatments for Parkinson's disease psychosis and is expanding into the Rett syndrome segment. The absence of direct analogs ensures premium pricing power, which is offset by insurance reimbursements.

To identify the sector's fundamental leaders, the analyst evaluates EPS TTM as net income allocated per share over a year, which allows for filtering out market noise and measuring the security's real yield. Amid geopolitical risks hindering component logistics and ACADIA Pharmaceuticals (ACAD) clinical trials, the 12-month earnings per share history helps distinguish a temporary drawdown from a systemic production crisis.